Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday.
The company posted quarterly losses of 90 cents per share which missed the analyst consensus estimate of losses of 87 cents per share. The company reported quarterly sales of $15.600 million which missed the analyst consensus estimate of $18.097 million.
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) announced that it is entering an exclusive global licensing agreement with Arvinas and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant).
“The approval of VEPPANU is a defining achievement for Arvinas and reflects the …